The most serious form of chronic limb-threatening condition (CLTI), peripheral artery disease (PAD) in the legs affects an estimated two million Americans, especially with comorbidities such as diabetes. The PROMISE I and PROMISE II studies investigated the transcatheter deep vein arterialization (TADV) procedure using the LimFlow system, which bypasses blocked arteries in the leg and directs blood to the leg through the veins. In the pivotal PROMISE II study, after six months, 76 percent of patients achieved limb salvage and 76 percent had completely healed or healing wounds. Two-year results from both studies in 137 participants showed limb salvage in 68 percent of patients. In 82 percent of patients, the wounds healed or healed. TADV is a reliable and long-lasting therapy for patients with no other options who are at risk of amputation. Almost half of patients with vascular diseases die within five years of amputation, which is a higher mortality rate than for breast, colon or prostate cancer.